SSR-180,575

SSR-180,575

SSR-180,575 is a non-peptide antagonist of the neurokinin 1 receptor (NK1R). It was developed by Sanofi-Aventis and has been researched for its potential use in the treatment of depression and anxiety disorders.

History

SSR-180,575 was first synthesized by Sanofi-Aventis, a global pharmaceutical company. The compound was developed as part of a research program aimed at discovering new treatments for mood disorders. The development of SSR-180,575 was based on the hypothesis that antagonism of the NK1R could have therapeutic effects in depression and anxiety disorders.

Pharmacology

SSR-180,575 is a non-peptide antagonist of the NK1R. The NK1R is a G protein-coupled receptor that is activated by the neuropeptide substance P. Substance P is involved in many physiological processes, including the transmission of pain signals and the regulation of mood. By blocking the NK1R, SSR-180,575 can potentially modulate these processes.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of SSR-180,575 in the treatment of depression and anxiety disorders. However, the results of these trials have not been conclusive, and further research is needed to determine the therapeutic potential of this compound.

Potential Therapeutic Uses

The primary potential therapeutic use of SSR-180,575 is in the treatment of depression and anxiety disorders. These disorders are characterized by persistent feelings of sadness or worry, and they can significantly impact a person's quality of life. By modulating the activity of the NK1R, SSR-180,575 could potentially alleviate the symptoms of these disorders.

See Also

• Neurokinin 1 receptor
• Substance P
• Depression
• Anxiety disorders

References

‎